Compare Inovio Pharmaceuticals Inc (INO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Prudential PLC — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Prudential PLC trades at $27.55 (market cap $34.02B). The key difference: Prudential PLC is far larger — about 433.1× Inovio Pharmaceuticals Inc's market cap, and Prudential PLC pays a 1.94% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PUK | |
|---|---|---|
Market Cap | $78.55M | $34.02B |
Sector | Health | Financials |
52-Week High | $2.87 | $33.61 |
52-Week Low | $0.66 | $24.98 |
Enterprise Value | $49.56M | $35.46B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Prudential PLC (PUK) trades at $27.48, down 2.62% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income of $2.29B, while cash flow from operations surged to $3.61B. Recent news highlights a dividend declaration and strategic acquisitions, but shares face pressure from China regulatory concerns.
The outlook is mixed: attractive valuation and profitability support upside, but bearish technicals and China-related risks pose headwinds. Analyst consensus leans buy (50%), with institutional focus on execution of cost-cutting and geographic strategy. Key risks include regulatory changes in Asia and market volatility impacting near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
